GPA-0039

N/A

Report date: 2026/03/19 16:53:32

Base Information

Drug NameGPA-0039
Drug Alias NameIgG-based anti-GPRC5D/CD3 bispecific TRABs (Chugai Pharmaceutical)anti-CD3/anti-GPRC5D bispecific T-cell engager (Chugai Pharmaceutical)GPRC5DxCD3 bispecific antibody (Chugai Pharmaceutical)anti-GPRC5D/CD3 bispecific mAb (Chugai Pharmaceutical)IgG-based anti-GPRC5D/CD3 T cell-redirecting bispecific humanized mAb (Chugai Pharmaceutical) +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > T cell engagers
Mechanisms of ActionG-protein coupled receptor family C group 5member D modulatorsT lymphocytes stimulantsT cell surface glycoprotein CD3 modulators +[4] 
TargetsG-protein coupled receptor family C group 5member DT cell surface glycoprotein CD3
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesChugai Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChugai Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A